insiderwall
Menu
SuperinvestorInsider
Solid Biosciences Inc. SLDB

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Solid Biosciences Inc. is a precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its lead candidate, SGT-003, targets Duchenne muscular dystrophy and is in phase 1/2 clinical trials. The company advances a diversified pipeline including SGT-212 for Friedreich's ataxi

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees121
TickerSLDB

Statistics

Market Cap$725.2M
Revenue (TTM)
Net Income-$174.3M
Net Margin
EPS$-1.99
P/E0.15
P/S
P/B1.90
EV/EBITDA-1.80
ROE-57.4%
Dividend Yield
Price$7.37

Data: Twelve Data · Revenue = mcap / P/S